Patents by Inventor Monica J. Huber
Monica J. Huber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10562967Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: May 8, 2018Date of Patent: February 18, 2020Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
-
Publication number: 20180251543Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: ApplicationFiled: May 15, 2018Publication date: September 6, 2018Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Publication number: 20180251541Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: ApplicationFiled: May 8, 2018Publication date: September 6, 2018Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
-
Patent number: 10000563Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: GrantFiled: July 12, 2016Date of Patent: June 19, 2018Assignee: ZYMOGENETICS, INC.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Patent number: 9994634Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: September 8, 2016Date of Patent: June 12, 2018Assignee: ZYMOGENETICS, INC.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
-
Publication number: 20160376362Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and IL-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: ApplicationFiled: September 8, 2016Publication date: December 29, 2016Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
-
Publication number: 20160311897Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: ApplicationFiled: July 12, 2016Publication date: October 27, 2016Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Patent number: 9464134Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: February 20, 2015Date of Patent: October 11, 2016Assignee: ZYMOGENETICS, INC.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
-
Patent number: 9416183Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: GrantFiled: September 23, 2014Date of Patent: August 16, 2016Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Publication number: 20150197566Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: ApplicationFiled: February 20, 2015Publication date: July 16, 2015Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
-
Patent number: 8992922Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: June 27, 2013Date of Patent: March 31, 2015Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
-
Publication number: 20150010553Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: ApplicationFiled: September 23, 2014Publication date: January 8, 2015Inventors: STEPHEN R. JASPERS, SCOTT R. PRESNELL, MONICA J. HUBER
-
Patent number: 8871467Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: GrantFiled: June 5, 2013Date of Patent: October 28, 2014Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Publication number: 20130309235Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: ApplicationFiled: June 27, 2013Publication date: November 21, 2013Applicant: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
-
Publication number: 20130288304Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: ApplicationFiled: June 5, 2013Publication date: October 31, 2013Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Patent number: 8557544Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: GrantFiled: July 2, 2012Date of Patent: October 15, 2013Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Patent number: 8496936Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: June 27, 2012Date of Patent: July 30, 2013Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
-
Patent number: 8481288Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.Type: GrantFiled: July 2, 2012Date of Patent: July 9, 2013Assignee: ZymoGenetics, Inc.Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
-
Patent number: 8333968Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: February 22, 2011Date of Patent: December 18, 2012Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
-
Publication number: 20120294862Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: ApplicationFiled: June 27, 2012Publication date: November 22, 2012Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber